On February 18, 2025, a significant milestone was achieved in the domestic medical aesthetics industry. Shanghai Moyang Biotechnology Co., Ltd. (hereinafter referred to as “Moyang Biotech”) successfully obtained the Class III Medical Device Registration Certificate from the National Medical Products Administration (NMPA) for its independently developed calcium hydroxyapatite microsphere-based facial filler (brand name: Aphranel®). This product marks China’s first domestically developed and compliant CaHA (calcium hydroxyapatite) facial filler, effectively filling a gap in the domestic market. CCRC MedTech, leveraging its exceptional clinical trial expertise and extensive project experience, provided robust support for the successful approval of “Aphranel.”
1. Empowering Industry Innovation with Professional Capabilities to Promote High-Quality Development in Medical Aesthetics
As a leading enterprise in the domestic clinical trial sector, CCRC MedTech has consistently been committed to driving technological innovation and standardized development in the medical aesthetics industry through scientific and rigorous clinical trial services. In the “Aphranel” project, CCRC MedTech fully utilized its professional strengths in the medical aesthetics field. By designing and executing high-standard, high-quality clinical trials, the company ensured the product’s safety, efficacy, and compliance, laying a solid foundation for groundbreaking advancements in the domestic CaHA facial filler sector.
2. Deepening Expertise in Medical Aesthetics to Build a Comprehensive Clinical Trial Service System
CCRC MedTech boasts extensive project experience in the medical aesthetics field, having successfully facilitated the approval of multiple medical aesthetics products, including facial fillers, skin repair materials, and laser beauty devices. The company’s professional team comprises seasoned clinical research experts, medical statisticians, and quality control specialists, all of whom possess years of experience in clinical research for medical aesthetics products and a profound understanding of industry trends and regulatory requirements. Supported by a robust quality management system and a clinical trial information management system, CCRC MedTech has achieved standardized, digitalized, and intelligent management of the entire clinical trial process, significantly enhancing project execution efficiency and data quality.
3. Global Vision in Medical Aesthetics to Empower a New Chapter in the Industry
The success of the “Aphranel” project not only marks a milestone in CCRC MedTech’s efforts to empower innovation in the medical aesthetics industry but also represents a significant step forward in the globalization and standardization of China’s medical aesthetics sector. By strictly adhering to international standards and continuously improving the quality of clinical trials, CCRC MedTech is helping Chinese medical aesthetics companies develop globally competitive products, offering high-quality medical aesthetics services to more consumers. Moving forward, CCRC MedTech will continue to expand its presence in the medical aesthetics field with a global perspective, deepening collaborations with leading international institutions and promoting the alignment of Chinese medical aesthetics standards with global benchmarks. Simultaneously, the company will actively explore the application of cutting-edge technologies such as artificial intelligence and big data in clinical trials, driving industry transformation through technological innovation. CCRC MedTech aims to support Chinese medical aesthetics companies in stepping onto the global stage, providing safer, more effective, and personalized medical aesthetics solutions to consumers worldwide, and jointly building an open and win-win global medical aesthetics ecosystem.
